{
    "ticker": "OTRKP",
    "name": "Outlook Therapeutics, Inc.",
    "description": "Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative ophthalmic therapies. Founded in 2010 and headquartered in Bridgewater, New Jersey, Outlook is dedicated to addressing unmet medical needs in the field of eye diseases. The company's lead product candidate, OTX-TKI, is an investigational treatment designed for patients with wet age-related macular degeneration (AMD), a leading cause of vision loss. Outlook Therapeutics aims to improve the quality of life for patients suffering from serious eye diseases by advancing its pipeline of therapies that are designed to enhance the effectiveness of existing treatments and provide meaningful clinical benefits. The company utilizes a unique formulation technology to deliver its therapies, which may lead to increased patient adherence and better treatment outcomes. With a robust development pipeline and a commitment to innovation, Outlook Therapeutics is poised to make a significant impact in the ophthalmology market as it seeks to bring new therapeutic options to patients and eye care professionals.",
    "industry": [
        "Biopharmaceuticals",
        "Ophthalmology"
    ],
    "headquarters": "Bridgewater, New Jersey, USA",
    "founded": "2010",
    "website": "https://www.outlooktherapeutics.com",
    "ceo": "Michael E. McGarry",
    "social_media": {
        "twitter": "https://twitter.com/OutlookThera",
        "linkedin": "https://www.linkedin.com/company/outlook-therapeutics/"
    },
    "investor_relations": "https://ir.outlooktherapeutics.com",
    "key_executives": [
        {
            "name": "Michael E. McGarry",
            "position": "CEO"
        },
        {
            "name": "Rohit J. Khosla",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "OTX-TKI"
            ]
        }
    ],
    "seo": {
        "meta_title": "Outlook Therapeutics, Inc. | Innovative Ophthalmic Therapies",
        "meta_description": "Explore Outlook Therapeutics, Inc., a leader in developing innovative ophthalmic therapies aimed at treating serious eye diseases. Learn more about their pipeline and commitment to patient care.",
        "keywords": [
            "Outlook Therapeutics",
            "Ophthalmology",
            "Biopharmaceuticals",
            "Eye Disease Treatment",
            "AMD",
            "OTX-TKI"
        ]
    },
    "faq": [
        {
            "question": "What is Outlook Therapeutics focused on?",
            "answer": "Outlook Therapeutics focuses on developing and commercializing innovative therapies for eye diseases."
        },
        {
            "question": "Who is the CEO of Outlook Therapeutics?",
            "answer": "Michael E. McGarry is the CEO of Outlook Therapeutics, Inc."
        },
        {
            "question": "Where is Outlook Therapeutics headquartered?",
            "answer": "Outlook Therapeutics is headquartered in Bridgewater, New Jersey, USA."
        },
        {
            "question": "What is the main product of Outlook Therapeutics?",
            "answer": "The main product candidate is OTX-TKI, aimed at treating wet age-related macular degeneration."
        },
        {
            "question": "When was Outlook Therapeutics founded?",
            "answer": "Outlook Therapeutics was founded in 2010."
        }
    ],
    "competitors": [
        "REGN",
        "BMY",
        "SNY",
        "RGEN"
    ],
    "related_stocks": [
        "AAPL",
        "AMGN",
        "GILD",
        "JNJ"
    ]
}